FDA's 510(k) Reform Proposals Released in October 2026 Are Drawing Industry Comment on Predicate Reliance Rules and the Impact on Class II Device Clearance Timelines

The FDA Center for Devices and Radiological Health released a proposed rule in early October 2026 that would implement the most significant structural changes to the 510(k) premarket notification pathway since its original establishment under the Medical Device Amendments of 1976. The proposal addresses longstanding concerns raised by the Government Accountability Office, academic researchers, and patient advocacy groups about the use of aging predicates in demonstrating substantial equivalence for new devices, and introduces performance standard requirements for specific device categories that would supplement or replace predicate-based substantial equivalence determinations. The medical device industry's initial response has ranged from cautious engagement to strong opposition, with large device companies and their trade associations filing detailed technical comments that highlight what they characterise as the practical and commercial consequences of the proposed changes for the speed and cost of bringing new devices to the US market.

The 510(k) Pathway and the Predicate Problem

The 510(k) substantial equivalence pathway allows medical device manufacturers to obtain FDA clearance by demonstrating that their new device is substantially equivalent to a legally marketed predicate device in terms of intended use, design, and technological characteristics. The pathway was designed to provide a faster and less costly route to market than the Pre-Market Approval pathway required for high-risk Class III devices, enabling innovation in the Class II device segment without requiring the full clinical evidence package that PMA demands. The pathway has been enormously commercially successful, accounting for approximately eighty percent of medical device marketing authorisations annually, but has attracted sustained criticism for allowing the use of predicates that may themselves be old, outdated, or have safety records that should preclude their continued use as comparators for new device clearances.

The FDA's own analysis, published alongside the proposed rule, identified a significant number of currently marketed 510(k)-cleared devices whose predicate chains included devices predating 1976 or devices that had subsequently been recalled or withdrawn from the market. The predicate daisy-chain phenomenon, where a new device uses as its predicate a device that was cleared using an older predicate and so on through multiple generations, has the practical effect of allowing substantial equivalence determinations to be made against device designs that may no longer represent appropriate benchmarks for safety and effectiveness given advances in technology and clinical understanding of device failure modes. The proposed rule would limit predicate age to ten years for most device categories and prohibit the use of devices with Class I or voluntary recalls within five years as predicates, directly addressing the most criticised aspects of current substantial equivalence practice.

Performance Standards and the Regulatory Workload

Beyond predicate reliance restrictions, the proposed rule introduces a framework for establishing mandatory performance standards for specific Class II device categories, within which clearance would require demonstration of performance meeting the standard rather than substantial equivalence to a predicate. The FDA has identified an initial list of device categories including certain cardiovascular diagnostic devices, implantable neurostimulators, and diagnostic imaging equipment as candidates for early performance standard development, with a schedule that would have the first standards published within three years of the proposed rule's finalisation.

Industry comment has focused particularly on the performance standard framework's implications for development timelines and costs. Performance standards require the generation of specific quantitative performance evidence through bench testing, preclinical studies, or clinical evaluation, depending on the device category and the nature of the standard. For device categories currently using well-established predicates to achieve straightforward substantial equivalence determinations, the introduction of mandatory performance standards effectively converts a regulatory pathway that required minimal original evidence generation into one that requires a defined evidence package analogous to, though typically less extensive than, a PMA application. Device companies estimate that development timelines could extend by twelve to twenty-four months and development costs could increase by two to five million dollars per submission for affected device categories, substantially altering the innovation economics of the Class II device segment.

Competitive and Investment Implications

The competitive implications of the proposed 510(k) reforms differ substantially between large device companies and the smaller MedTech innovators that have historically used the 510(k) pathway as the primary route for commercialising new device innovations. Large companies with substantial regulatory affairs organisations and established relationships with FDA review staff are better positioned to navigate a more demanding clearance process, though they will also face higher development costs and longer cycles for their Class II device pipelines. Smaller MedTech companies, venture-backed startups, and academic spinouts that rely on capital-efficient 510(k) clearance as a near-term commercial milestone are more acutely exposed to the proposed changes, since the combination of longer timelines and higher development costs extends the pre-revenue period that requires investor financing and reduces the internal rate of return projections that govern early-stage MedTech investment decisions.

Several MedTech-focused venture capital firms have publicly commented that the proposed 510(k) reforms, if implemented as drafted, would reduce the attractiveness of early-stage Class II device investment in the US market relative to EU MDR-compliant CE marking in Europe, despite European regulatory requirements having themselves become substantially more onerous under the Medical Device Regulation that replaced the former Medical Device Directive. The risk that innovation migrates away from the US market toward regulatory environments with more predictable and capital-efficient pathways to commercialisation is a concern that the FDA has acknowledged in its economic impact analysis accompanying the proposed rule, though the agency has argued that the safety and effectiveness benefits of the reforms justify the commercial cost impact.

Top 10 Companies

1. Medtronic , World's largest medical device company by revenue, with a broad Class II device portfolio across cardiac, neuromodulation, and surgical categories that are directly affected by the proposed predicate and performance standard changes.
2. Abbott Laboratories , Major device manufacturer with significant cardiovascular diagnostic and monitoring device lines in Class II categories identified as early candidates for performance standard development.
3. BD Becton Dickinson , Diversified device company with a large portfolio of 510(k)-cleared diagnostic, vascular access, and procedural devices that would be subject to predicate age and recall restrictions under the proposed rule.
4. Stryker , Orthopaedic and surgical device manufacturer whose Class II product lines in surgical instruments and imaging equipment face predicate limitation and performance standard implications.
5. Boston Scientific , Interventional cardiology and endoscopy device company with substantial 510(k) clearance activity that will be affected by the proposed predicate restriction and the performance standard framework for cardiovascular device categories.
6. Philips Healthcare , Diagnostic imaging equipment manufacturer in device categories identified as early candidates for performance standard development, with significant regulatory affairs resources engaged in the comment process.
7. AdvaMed , US medical device industry trade association coordinating the industry's formal comment response to the proposed 510(k) reforms, representing both large company and small company perspectives.
8. Intuitive Surgical , Robotic surgery system company whose Class II surgical device components would be subject to predicate and performance standard changes that affect the development economics of its next-generation system pipeline.
9. Hologic , Women's health device company with a significant Class II diagnostic and surgical device portfolio, actively engaged in commenting on the proposed rule's implications for its mammography and surgical systems product development roadmaps.
10. Masimo , Patient monitoring device company whose pulse oximetry and monitoring systems are in Class II categories, with the proposed performance standard framework potentially affecting clearance strategies for next-generation monitoring platforms.